Overview

Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Status:
Recruiting

Trial end date:
2024-02-01

Target enrollment:

Participant gender:

Summary

The main purpose of this research study is to find out if the combination of acalabrutinib and high frequency low dose subcutaneous rituximab is safe and effective in patients who have previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Phase:

Phase 2

Details

Lead Sponsor:

University of Rochester

Treatments:

Acalabrutinib
Rituximab